<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369053</url>
  </required_header>
  <id_info>
    <org_study_id>FRNM-004</org_study_id>
    <nct_id>NCT04369053</nct_id>
  </id_info>
  <brief_title>Prevention of Colorectal Cancer Through Multiomics Blood Testing</brief_title>
  <acronym>PREEMPT CRC</acronym>
  <official_title>Prevention of Colorectal Cancer Through Multiomics Blood Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Freenome Holdings Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Freenome Holdings Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PREEMPT CRC study is a prospective multi-center observational study to validate a
      blood-based test for the early detection of colorectal cancer by collecting blood samples
      from average-risk participants who will undergo a routine screening colonoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Freenome is using a type of artificial intelligence, called machine learning, to identify
      patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this
      prospective multi-center observational study is to validate a blood-based test for the
      detection of colorectal cancer by collecting blood samples from average-risk participants who
      will undergo a routine screening colonoscopy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity for CRC of the Freenome test</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of the Freenome test</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">14000</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Rectal Cancer</condition>
  <condition>Colon Neoplasm</condition>
  <condition>Colon Diseases</condition>
  <condition>Colon Lesion</condition>
  <condition>Colon Polyp</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Polyp</condition>
  <condition>Adenoma</condition>
  <condition>Rectal Diseases</condition>
  <condition>Gastrointestinal Tract Cancers</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Freenome test</intervention_name>
    <description>Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled. Participants will undergo blood collection and will then complete a standard-of-care screening colonoscopy.</description>
    <other_name>Single Group Assignment</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood specimens will be de-identified and used to validate the performance characteristics of
      the Freenome test.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants aged between 45 and 85 who are eligible for CRC screening and scheduled for a
        standard-of-care screening colonoscopy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Inclusion Criteria

          1. 45-85 years of age

          2. Willing to undergo a standard-of-care screening colonoscopy

          3. Able and willing to provide a blood sample

          4. Able and willing to sign informed consent

        Key Exclusion Criteria

          1. Known hereditary gastrointestinal cancer syndrome (for example, hereditary
             non-polyposis CRC syndrome (HNPCC) or Lynch syndrome, or familial adenomatous
             polyposis (FAP)

          2. Personal history 2.1 CRC or colorectal adenoma 2.2 Inflammatory bowel disease (IBD),
             including chronic ulcerative colitis (CUC) and crohn's disease (CD) 2.3 Colonoscopy in
             the 9 years preceding enrollment 2.4 Stool DNA testing in the 2 years preceding
             enrollment 2.5 Symptoms of lower gastrointestinal tract disease warranting
             colonoscopic evaluation

          3. A medical condition which, in the opinion of the Investigator, should preclude
             enrollment in the study

          4. Participated or currently participating in a clinical research study in which an
             experimental medication has been administered during the 60 days up to and including
             the date of providing informed consent or may be administered through the time of the
             colonoscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Girish Putcha, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Freenome Holdings Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aasma Shaukat, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Theodore R Levin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Permanente Medical Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Valencia, MS</last_name>
    <phone>312-324-3397</phone>
    <email>research@freenome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chuanbo Xu, PhD</last_name>
    <email>research@freenome.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shraddha Pattel</last_name>
      <email>spatel@iacthealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quincy Medical Group</name>
      <address>
        <city>Quincy</city>
        <state>Illinois</state>
        <zip>62301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Ely</last_name>
      <email>jely@quincymedgroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>American Health Network of Indiana, LLC</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Shaeffer</last_name>
      <email>laura_shaeffer@ahni.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Artificial Intelligence</keyword>
  <keyword>Liquid Biopsy</keyword>
  <keyword>Blood Test Cancer</keyword>
  <keyword>Cancer Diagnostic</keyword>
  <keyword>Genomics</keyword>
  <keyword>Genomics Test</keyword>
  <keyword>CRC</keyword>
  <keyword>Cancer Screening</keyword>
  <keyword>Cancer Early Detection Test</keyword>
  <keyword>Screening</keyword>
  <keyword>Colonoscopy</keyword>
  <keyword>Machine Learning</keyword>
  <keyword>Freenome Test</keyword>
  <keyword>Colorectal Cancer (CRC)</keyword>
  <keyword>Colorectal Cancer Screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Rectal Diseases</mesh_term>
    <mesh_term>Colonic Diseases</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

